Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma

British Journal of Pharmacology

Volumn 171, Issue 23, 2014, Pages 5330-5344

  Sonawane, Poonam ^a,b   Cho, Hwang Eui ^a,b   Tagde, Ashujit ^a,b   Verlekar, Dattesh ^a,b   Yu, Alice L ^c,d   Reynolds, C Patrick ^a,b,e   Kang, Min H ^a,b,e  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TEXAS TECH UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 OXOISOTRETINOIN; ISOENZYME; ISOTRETINOIN; MESSENGER RNA; 4-OXORETINOIC ACID; ANTINEOPLASTIC AGENT; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ASSAY; GLUCURONIDATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIVER MICROSOME; MOUSE; MYCN GENE; NERVE FIBER GROWTH; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; MICROSOME; NEURITE; PHASE 3 CLINICAL TRIAL; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; HUMANS; ISOTRETINOIN; MICE, INBRED BALB C; MICROSOMES; NEURITES; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; RECEPTORS, RETINOIC ACID; RNA, MESSENGER; TANDEM MASS SPECTROMETRY; TRETINOIN;

EID: 84925949530     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12846     Document Type: Article

References (61)

1. Abemayor E, Sidell N, (1989). Human neuroblastoma cell lines as models for the in vitro study of neoplastic and neuronal cell differentiation. Environ Health Perspect 80: 3-15.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: nuclear hormone receptors. Br J Pharmacol 170: 1652-1675.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol 170: 1797-1867.
4. Alvarez S, Bourguet W, Gronemeyer H, de Lera AR, (2011). Retinoic acid receptor modulators: a perspective on recent advances and promises. Expert Opin Ther Pat 21: 55-63.
5. Burkhart CA, Cheng AJ, Madafiglio J, Kavallaris M, Mili M, Marshall GM, et al. (2003). Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. J Natl Cancer Inst 95: 1394-1403.
6. Caren H, Kryh H, Nethander M, Sjoberg RM, Trager C, Nilsson S, et al. (2010). High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U S A 107: 4323-4328.
7. Cheung B, Hocker JE, Smith SA, Norris MD, Haber M, Marshall GM, (1998). Favorable prognostic significance of high-level retinoic acid receptor beta expression in neuroblastoma mediated by effects on cell cycle regulation. Oncogene 17: 751-759.
8. Clagett-Dame M, Verhalen TJ, Biedler JL, Repa JJ, (1993). Identification and characterization of all-trans-retinoic acid receptor transcripts and receptor protein in human neuroblastoma cells. Arch Biochem Biophys 300: 684-693.
9. Finklestein JZ, Krailo MD, Lenarsky C, Ladisch S, Blair GK, Reynolds CP, et al. (1992). 13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Children's Cancer Study Group. Med Pediatr Oncol 20: 307-311.
10. Fotsis T, Breit S, Lutz W, Rossler J, Hatzi E, Schwab M, et al. (1999). Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells. Eur J Biochem 263: 757-764.
11. Frgala T, Kalous O, Proffitt RT, Reynolds CP, (2007). A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 6: 886-897.
12. Greenberg BR, Durie BG, Barnett TC, Meyskens FL Jr, (1985). Phase I-II study of 13-cis-retinoic acid in myelodysplastic syndrome. Cancer Treat Rep 69: 1369-1374.
13. Hadjidaniel MD, Reynolds CP, (2010). Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by 13-cis-retinoic acid is mediated by the antiapoptotic Bcl-2 family proteins. Mol Cancer Ther 9: 3164-3174.
14. Haussler M, Sidell N, Kelly M, Donaldson C, Altman A, Mangelsdorf D, (1983). Specific high-affinity binding and biologic action of retinoic acid in human neuroblastoma cell lines. Proc Natl Acad Sci U S A 80: 5525-5529.
15. Hua S, Kittler R, White KP, (2009). Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell 137: 1259-1271.
16. Iwanaka T, Yamamoto K, Ogawa Y, Arai M, Ito M, Kishimoto H, et al. (2001). Maturation of mass-screened localized adrenal neuroblastoma. J Pediatr Surg 36: 1633-1636.
17. Kanemaru KK, Tuthill MC, Takeuchi KK, Sidell N, Wada RK, (2008). Retinoic acid induced downregulation of MYCN is not mediated through changes in Sp1/Sp3. Pediatr Blood Cancer 50: 806-811.
18. Kang MH, Wan Z, Kang Y, Sposto R, Reynolds CP, (2008). Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst 100: 580-595.
19. Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP, (2010). National cancer institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer 56: 239-249.
20. Keshelava N, Seeger RC, Groshen S, Reynolds CP, (1998). Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 58: 5396-5405.
21. Khan AA, Villablanca JG, Reynolds CP, Avramis VI, (1996). Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation. Cancer Chemother Pharmacol 39: 34-41.
22. Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, et al. (2006). Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 98: 441-450.
23. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
24. Kim JS, Lee H, Kim H, Shim YM, Han J, Park J, et al. (2004). Promoter methylation of retinoic acid receptor beta 2 and the development of second primary lung cancers in non-small-cell lung cancer. J Clin Oncol 22: 3443-3450.
25. Kramps C, Strieder V, Sapetschnig A, Suske G, Lutz W, (2004). E2F and Sp1/Sp3 Synergize but are not sufficient to activate the MYCN gene in neuroblastomas. J Biol Chem 279: 5110-5117.
26. Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, et al. (2013). Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol 14: 999-1008.
27. Li C, Einhorn PA, Reynolds CP, (1994). Expression of retinoic acid receptors alpha, beta, and gamma in human neuroblastoma cell lines. Prog Clin Biol Res 385: 221-227.
28. Lippman SM, Kessler JF, Al-Sarraf M, Alberts DS, Itri LM, Mattox D, et al. (1988). Treatment of advanced squamous cell carcinoma of the head and neck with isotretinoin: a phase II randomized trial. Invest New Drugs 6: 51-56.
29. Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, et al. (2001). Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 93: 605-618.
30. London WB, Castel V, Monclair T, Ambros PF, Pearson ADJ, Cohn SL, et al. (2011). Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the international neuroblastoma risk group Project. J Clin Oncol 29: 3286-3292.
31. Lutz W, Schwab M, (1997). In vivo regulation of single copy and amplified N-myc in human neuroblastoma cells. Oncogene 15: 303-315.
32. Maris JM, Matthay KK, (1999). Molecular biology of neuroblastoma. J Clin Oncol 17: 2264-2279.
33. Maris JM, Hogarty MD, Bagatell R, Cohn SL, (2007). Neuroblastoma. Lancet 369: 2106-2120.
34. Marshall GM, Cheung B, Stacey KP, Norris MD, Haber M, (1994). Regulation of retinoic acid receptor alpha expression in human neuroblastoma cell lines and tumor tissue. Anticancer Res 14: 437-441.
35. Masters JR, Thomson JA, Daly-Burns B, Reid YA, Dirks WG, Packer P, et al. (2001). Short tandem repeat profiling provides an international reference standard for human cell lines. PNAS 98: 8012-8017.
36. Matthay KK, O'Leary MC, Ramsay NK, Villablanca J, Reynolds CP, Atkinson JB, et al. (1995). Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results. Eur J Cancer 31A: 572-575.
37. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. (1999). Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341: 1165-1173.
38. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. (2009). Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group study. J Clin Oncol 27: 1007-1013.
39. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
40. Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T, (2003). Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 123: 369-375.
41. Park JR, Villablanca JG, London WB, Gerbing RB, Haas-Kogan D, Adkins ES, et al. (2009). Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group. Pediatr Blood Cancer 52: 44-50.
42. Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KM, et al. (2013). Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer 60: 985-993.
43. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-1106.
44. Pelengaris S, Khan M, Evan GI, (2002). Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109: 321-334.
45. Pession A, Tonelli R, (2005). The MYCN oncogene as a specific and selective drug target for peripheral and central nervous system tumors. Curr Cancer Drug Targets 5: 273-283.
46. Peverali FA, Orioli D, Tonon L, Ciana P, Bunone G, Negri M, et al. (1996). Retinoic acid-induced growth arrest and differentiation of neuroblastoma cells are counteracted by N-myc and enhanced by max overexpressions. Oncogene 12: 457-462.
47. Reynolds CP, (2000). Differentiating agents in pediatric malignancies: retinoids in neuroblastoma. Curr Oncol Rep 2: 511-518.
48. Reynolds CP, Kane DJ, Einhorn PA, Matthay KK, Crouse VL, Wilbur JR, et al. (1991). Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog Clin Biol Res 366: 203-211.
49. Reynolds CP, Schindler PF, Jones DM, Gentile JL, Proffitt RT, Einhorn PA, (1994). Comparison of 13-cis-retinoic acid to trans-retinoic acid using human neuroblastoma cell lines. Prog Clin Biol Res 385: 237-244.
50. Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ, (2003). Retinoid therapy of high-risk neuroblastoma. Cancer Lett 197: 185-192.
51. Rubin GM, Tozer TN, (1986). Hepatic binding and Michaelis-Menten metabolism of drugs. J Pharm Sci 75: 660-663.
52. Schug TT, Berry DC, Shaw NS, Travis SN, Noy N, (2007). Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 129: 723-733.
53. Seeger RC, Reynolds CP, (1991). Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation. Pediatr Clin North Am 38: 393-424.
54. Sidell N, (1982). Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J Natl Cancer Inst 68: 589-596.
55. Sidell N, Altman A, Haussler MR, Seeger RC, (1983). Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines. Exp Cell Res 148: 21-30.
56. Thiele CJ, Reynolds CP, Israel MA, (1985). Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 313: 404-406.
57. Veal GJ, Cole M, Errington J, Pearson AD, Foot AB, Whyman G, et al. (2007). Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma-a study of the United Kingdom Children's Cancer Study Group. Br J Cancer 96: 424-431.
58. Veal GJ, Errington J, Rowbotham SE, Illingworth NA, Malik G, Cole M, et al. (2013). Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma. Clin Cancer Res 19: 469-479.
59. Villablanca JG, Khan AA, Avramis VI, Seeger RC, Matthay KK, Ramsay NK, et al. (1995). Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 13: 894-901.
60. Wuarin L, Chang B, Wada R, Sidell N, (1994). Retinoic acid up-regulates nuclear retinoic acid receptor-alpha expression in human neuroblastoma cells. Int J Cancer 56: 840-845.
61. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. (2010). Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363: 1324-1334.